Europe funds R&D (research and development) programme:
This article was originally published in Clinica
Executive Summary
The European Parliament has endorsed a compromise version of the fifth framework programme on research spending in the EU, following a final round of conciliation talks between the Parliament and the Council. The final budget has been set at ECU14.96 billion ($16.7 billion), an increase of 4.6%, with the largest sectoral increase (42%) going to the biosciences. Parliament rejected an attempt by the Greens to refuse funding for research based on using foetal tissues and pre-implantation diagnosis "until the ethical issues have been fully and publicly evaluated".
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.